Payment overview · 2025
General Payments
$691.77
31 reported records · 14 companies
Healthcare provider profile · identity verified
Efrain A Torres, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Geriatric Medicine · NEW BEDFORD, MA · NPI 1003859265
Verified facts
What the public records show
CMS Open Payments records show Efrain A Torres, M.D. received $691.77 in general payments during 2025 across 31 reported records.
Lilly USA, LLC accounted for 23.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Linzess, Paxlovid, Rexulti, Yupelri.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Lumigan by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BEVESPI AEROSPHERE as an associated drug or biological on 763 records involving 473 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Bevespi Aerosphere by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 362 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 117 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fiasp as an associated drug or biological on 15 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Fiasp by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 1201 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Paxlovid by this doctor in 2024.
Viatris Specialty LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported YUPELRI as an associated drug or biological on 26927 records involving 11152 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Yupelri by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $163.04 | 23.6% | 6 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $87.01 | 12.6% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $72.87 | 10.5% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $69.51 | 10.1% | 3 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $63.40 | 9.2% | 3 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $47.52 | 6.9% | 2 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $37.62 | 5.4% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $35.57 | 5.1% | 2 | 2025 |
| RGH Enterprises LLC | Unresolved — no canonical attribution shown | $23.83 | 3.4% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $21.16 | 3.1% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.91 | 3.0% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $19.46 | 2.8% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $15.15 | 2.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.72 | 2.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $691.77 | 31 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $119.84 | 4 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $87.01 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $72.87 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $69.51 | 3 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $63.40 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $43.20 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $43.20 | 2 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $37.62 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $35.57 | 2 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $26.48 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $21.16 | 1 | 2025 |
Source payment records
|
|||||
| VOWST Normalized: vowst |
Biological | Aimmune Therapeutics, Inc. | $21.04 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $20.91 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $19.46 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $15.15 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $14.72 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 362 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 83 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 37 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| YUPELRI yupelri |
2025 | Yupelri | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
83 | 19 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BEVESPI AEROSPHERE open payments reported associated product |
CMS Open Payments — General Payments 763 supporting records · 473 recipient NPIs · example record 1206131384 |
Bevespi Aerosphere · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
60 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
362 | 51 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
117 | 20 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Fiasp open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 15 recipient NPIs · example record 1188262936 |
Fiasp · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
29 | 29 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
1201 | 125 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
37 | 36 |
| Viatris Specialty LLC Exact reporting entity; no affiliate inference |
2025 | YUPELRI open payments reported associated product |
CMS Open Payments — General Payments 26927 supporting records · 11152 recipient NPIs · example record 1238463489 |
Yupelri · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Trazodone Hcl | Trazodone Hcl | 2265 | 275 |
| Atorvastatin Calcium | Atorvastatin Calcium | 2137 | 301 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1562 | 185 |
| Amlodipine Besylate | Amlodipine Besylate | 1412 | 231 |
| Eliquis | Apixaban | 1201 | 125 |
| Furosemide | Furosemide | 1185 | 164 |
| Omeprazole | Omeprazole | 1054 | 182 |
| Lisinopril | Lisinopril | 940 | 179 |
| Pantoprazole Sodium | Pantoprazole Sodium | 919 | 169 |
| Metoprolol Succinate | Metoprolol Succinate | 903 | 122 |
| Quetiapine Fumarate | Quetiapine Fumarate | 878 | 87 |
| Mirtazapine | Mirtazapine | 836 | 122 |
| Metoprolol Tartrate | Metoprolol Tartrate | 757 | 115 |
| Potassium Chloride | Potassium Chloride | 750 | 106 |
| Gabapentin | Gabapentin | 744 | 116 |
| Metformin Hcl | Metformin Hcl | 693 | 119 |
| Simvastatin | Simvastatin | 670 | 125 |
| Sertraline Hcl | Sertraline Hcl | 658 | 84 |
| Escitalopram Oxalate | Escitalopram Oxalate | 547 | 93 |
| Memantine Hcl | Memantine Hcl | 522 | 57 |
| Tamsulosin Hcl | Tamsulosin Hcl | 514 | 84 |
| Donepezil Hcl | Donepezil Hcl | 467 | 55 |
| Citalopram Hbr | Citalopram Hydrobromide | 449 | 58 |
| Januvia | Sitagliptin Phosphate | 439 | 46 |
| Losartan Potassium | Losartan Potassium | 432 | 64 |
| Tramadol Hcl | Tramadol Hcl | 412 | 82 |
| Clopidogrel | Clopidogrel Bisulfate | 375 | 43 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 373 | 65 |
| Jardiance | Empagliflozin | 362 | 51 |
| Divalproex Sodium | Divalproex Sodium | 357 | 56 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 330 | 62 |
| Pravastatin Sodium | Pravastatin Sodium | 311 | 50 |
| Warfarin Sodium | Warfarin Sodium | 303 | 22 |
| Alendronate Sodium | Alendronate Sodium | 278 | 43 |
| Hydrochlorothiazide | Hydrochlorothiazide | 264 | 43 |
| Tradjenta | Linagliptin | 253 | 25 |
| Allopurinol | Allopurinol | 251 | 46 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 247 | 26 |
| Prednisone | Prednisone | 245 | 80 |
| Lorazepam | Lorazepam | 238 | 50 |
| Olanzapine | Olanzapine | 233 | 32 |
| Alprazolam | Alprazolam | 219 | 28 |
| Xarelto | Rivaroxaban | 208 | 22 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 205 | 44 |
| Levetiracetam | Levetiracetam | 202 | 30 |
| Fluoxetine Hcl | Fluoxetine Hcl | 195 | 25 |
| Montelukast Sodium | Montelukast Sodium | 195 | 26 |
| Fluticasone Propionate | Fluticasone Propionate | 193 | 61 |
| Famotidine | Famotidine | 191 | 40 |
| Carvedilol | Carvedilol | 189 | 24 |
| Risperidone | Risperidone | 186 | 24 |
| Glipizide | Glipizide | 185 | 33 |
| Latanoprost | Latanoprost | 183 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 179 | 85 |
| Duloxetine Hcl | Duloxetine Hcl | 178 | 32 |
| Ondansetron Hcl | Ondansetron Hcl | 177 | 65 |
| Celecoxib | Celecoxib | 175 | 24 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 169 | 20 |
| Doxycycline Hyclate | Doxycycline Hyclate | 165 | 73 |
| Finasteride | Finasteride | 159 | 27 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 158 | 40 |
| Oxycodone Hcl | Oxycodone Hcl | 155 | 45 |
| Bupropion Hcl Sr | Bupropion Hcl | 148 | 20 |
| Bumetanide | Bumetanide | 146 | 23 |
| Baclofen | Baclofen | 143 | 30 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 142 | 20 |
| Tizanidine Hcl | Tizanidine Hcl | 134 | 19 |
| Buspirone Hcl | Buspirone Hcl | 133 | 23 |
| Nystatin | Nystatin | 131 | 49 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 130 | 16 |
| Torsemide | Torsemide | 125 | 18 |
| Clonazepam | Clonazepam | 123 | 18 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 118 | 56 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 117 | 23 |
| Trulicity | Dulaglutide | 117 | 20 |
| Atenolol | Atenolol | 116 | 16 |
| Ibuprofen | Ibuprofen | 116 | 36 |
| Lactulose | Lactulose | 114 | 14 |
| Rivastigmine | Rivastigmine Tartrate | 114 | 12 |
| Lansoprazole | Lansoprazole | 112 | 16 |
| Ventolin Hfa | Albuterol Sulfate | 112 | 44 |
| Hydralazine Hcl | Hydralazine Hcl | 111 | 20 |
| Pregabalin | Pregabalin | 111 | 16 |
| Doxazosin Mesylate | Doxazosin Mesylate | 110 | 23 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 106 | 23 |
| Sucralfate | Sucralfate | 106 | 14 |
| Levofloxacin | Levofloxacin | 105 | 69 |
| Paroxetine Hcl | Paroxetine Hcl | 105 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 104 | 12 |
| Meloxicam | Meloxicam | 99 | 23 |
| Benztropine Mesylate | Benztropine Mesylate | 97 | 13 |
| Cephalexin | Cephalexin | 92 | 48 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 91 | 80 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 88 | 76 |
| Topiramate | Topiramate | 87 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 86 | 15 |
| Linzess | Linaclotide | 83 | 19 |
| Breo Ellipta | Fluticasone/Vilanterol | 82 | 25 |
| Repaglinide | Repaglinide | 82 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 79 | 13 |
| Aripiprazole | Aripiprazole | 77 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 77 | 40 |
| Admelog Solostar | Insulin Lispro | 76 | 12 |
| Incruse Ellipta | Umeclidinium Bromide | 76 | 11 |
| Enalapril Maleate | Enalapril Maleate | 75 | 11 |
| Ezetimibe | Ezetimibe | 74 | 12 |
| Spironolactone | Spironolactone | 74 | 19 |
| Lamotrigine | Lamotrigine | 73 | 12 |
| Nifedipine Er | Nifedipine | 73 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 70 | 46 |
| Digoxin | Digoxin | 70 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 70 | suppressed |
| Valsartan | Valsartan | 70 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 68 | 26 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 68 | 13 |
| Metformin Hcl Er | Metformin Hcl | 68 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 65 | 20 |
| Ketoconazole | Ketoconazole | 62 | 17 |
| Memantine Hcl Er | Memantine Hcl | 62 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 60 | 25 |
| Constulose | Lactulose | 59 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 59 | 14 |
| Diltiazem Hcl | Diltiazem Hcl | 58 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 58 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 57 | 17 |
| Erythromycin | Erythromycin Base | 57 | 29 |
| Lovastatin | Lovastatin | 57 | suppressed |
| Perphenazine | Perphenazine | 57 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 56 | 20 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 56 | 40 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 54 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 53 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 52 | 12 |
| Clonidine Hcl | Clonidine Hcl | 51 | suppressed |
| Methimazole | Methimazole | 50 | suppressed |
| Budesonide | Budesonide | 47 | suppressed |
| Primidone | Primidone | 47 | suppressed |
| Azithromycin | Azithromycin | 46 | 36 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 46 | 31 |
| Irbesartan | Irbesartan | 46 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 45 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 45 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 44 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 43 | 20 |
| Amitriptyline Hcl | Amitriptyline Hcl | 41 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 41 | 19 |
| Humalog Kwikpen U-100 | Insulin Lispro | 41 | 14 |
| Colchicine | Colchicine | 40 | suppressed |
| Permethrin | Permethrin | 40 | 18 |
| Rexulti | Brexpiprazole | 40 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 40 | 26 |
| Timolol Maleate | Timolol Maleate | 40 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 39 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 39 | suppressed |
| Fentanyl | Fentanyl | 38 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 38 | suppressed |
| Myrbetriq | Mirabegron | 38 | suppressed |
| Nyamyc | Nystatin | 38 | 19 |
| Unifine Pentips | Pen Needle, Diabetic | 38 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 37 | 36 |
| Dicyclomine Hcl | Dicyclomine Hcl | 36 | suppressed |
| Glimepiride | Glimepiride | 36 | suppressed |
| Glipizide Er | Glipizide | 36 | suppressed |
| Nitroglycerin | Nitroglycerin | 36 | 30 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 36 | suppressed |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 35 | 23 |
| Valacyclovir | Valacyclovir Hcl | 35 | suppressed |
| Clotrimazole | Clotrimazole | 34 | suppressed |
| Fluconazole | Fluconazole | 34 | 21 |
| Gemfibrozil | Gemfibrozil | 34 | suppressed |
| Haloperidol | Haloperidol | 34 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 34 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 33 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 33 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 33 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 32 | suppressed |
| Bupropion Xl | Bupropion Hcl | 31 | suppressed |
| Enulose | Lactulose | 31 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 31 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 31 | suppressed |
| Anastrozole | Anastrozole | 30 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 30 | 29 |
| Enoxaparin Sodium | Enoxaparin Sodium | 30 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 30 | suppressed |
| Veltassa | Patiromer Calcium Sorbitex | 30 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 30 | suppressed |
| Xifaxan | Rifaximin | 30 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 29 | 29 |
| Albuterol Sulfate | Albuterol Sulfate | 29 | 23 |
| Galantamine Er | Galantamine Hbr | 29 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 29 | 15 |
| Labetalol Hcl | Labetalol Hcl | 29 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 28 | suppressed |
| Humalog | Insulin Lispro | 27 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 26 | suppressed |
| Gemtesa | Vibegron | 26 | suppressed |
| Novolog Flexpen | Insulin Aspart | 26 | suppressed |
| Nystop | Nystatin | 26 | 18 |
| Ramipril | Ramipril | 26 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 26 | 13 |
| Ceftriaxone | Ceftriaxone Sodium | 25 | 13 |
| Levemir Flexpen | Insulin Detemir | 25 | suppressed |
| Insulin Lispro | Insulin Lispro | 24 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 24 | suppressed |
| Rhopressa | Netarsudil Mesylate | 24 | suppressed |
| Calcitriol | Calcitriol | 23 | suppressed |
| Entresto | Sacubitril/Valsartan | 23 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 23 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 22 | suppressed |
| Folic Acid | Folic Acid | 22 | suppressed |
| Hydrocortisone | Hydrocortisone | 22 | 14 |
| Morphine Sulfate | Morphine Sulfate | 22 | 17 |
| Naproxen | Naproxen | 22 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 22 | suppressed |
| Oxycontin | Oxycodone Hcl | 22 | suppressed |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 21 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 21 | suppressed |
| Ondansetron Odt | Ondansetron | 21 | 15 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 20 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 20 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 20 | suppressed |
| Lubiprostone | Lubiprostone | 20 | suppressed |
| Ozempic | Semaglutide | 20 | suppressed |
| Sotalol | Sotalol Hcl | 20 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 20 | suppressed |
| Trospium Chloride | Trospium Chloride | 20 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 19 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 19 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 19 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 19 | suppressed |
| Novolog | Insulin Aspart | 19 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 19 | suppressed |
| Scopolamine | Scopolamine | 19 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 18 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 18 | suppressed |
| Indapamide | Indapamide | 18 | suppressed |
| Metronidazole | Metronidazole | 18 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 18 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 17 | suppressed |
| Dutasteride | Dutasteride | 17 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 17 | suppressed |
| Lumigan | Bimatoprost | 17 | suppressed |
| Procto-Med Hc | Hydrocortisone | 17 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 17 | 15 |
| Amoxicillin | Amoxicillin | 16 | suppressed |
| Cefadroxil | Cefadroxil | 16 | suppressed |
| Cilostazol | Cilostazol | 16 | suppressed |
| Formoterol Fumarate | Formoterol Fumarate | 16 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 15 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 15 | 11 |
| Levemir | Insulin Detemir | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 15 | suppressed |
| Restasis | Cyclosporine | 15 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 15 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 15 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 15 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 14 | suppressed |
| Cholestyramine Light | Cholestyramine | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 14 | suppressed |
| Letrozole | Letrozole | 14 | suppressed |
| Nateglinide | Nateglinide | 14 | suppressed |
| Ramelteon | Ramelteon | 14 | suppressed |
| Simbrinza | Brinzolamide/Brimonidine Tart | 14 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 14 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 13 | suppressed |
| Carbamazepine | Carbamazepine | 13 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 13 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 13 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 13 | suppressed |
| Nadolol | Nadolol | 13 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 13 | suppressed |
| Vyzulta | Latanoprostene Bunod | 13 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 12 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 12 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 12 | suppressed |
| Klor-Con 10 | Potassium Chloride | 12 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 12 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 12 | suppressed |
| Olanzapine Odt | Olanzapine | 12 | suppressed |
| Risperidone Odt | Risperidone | 12 | suppressed |
| Roflumilast | Roflumilast | 12 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 11 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 11 | suppressed |
| Fluocinonide | Fluocinonide | 11 | suppressed |
| Jantoven | Warfarin Sodium | 11 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 11 | 11 |
| Methazolamide | Methazolamide | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 11 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Yupelri | Revefenacin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $691.77 · 31 records | Lilly USA, LLC | ACCRUFER, AIRSUPRA, CAPLYTA, FREESTYLE LIBRE 3, JARDIANCE, LINZESS, MOUNJARO, Ohtuvayre, PAXLOVID, REXULTI, VOQUEZNA, VOWST, Wegovy, YUPELRI, ZENPEP, ZEPBOUND | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error